Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Non-Current Liabilities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $407.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $407.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $407.7 million, a N/A change, with the full-year FY2024 number at $438.0 million, changed 0.07% from a year prior.
  • Total Non-Current Liabilities was $407.7 million for Q3 2025 at Cartesian Therapeutics, down from $428.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $438.3 million in Q4 2023 to a low of $32.6 million in Q3 2023.
  • A 5-year average of $239.2 million and a median of $150.9 million in 2021 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 728.24% in 2023; the steepest drop was 45.54% in 2023.
  • Cartesian Therapeutics' Total Non-Current Liabilities stood at $144.1 million in 2021, then tumbled by 63.28% to $52.9 million in 2022, then skyrocketed by 728.24% to $438.3 million in 2023, then decreased by 0.07% to $438.0 million in 2024, then decreased by 6.92% to $407.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Total Non-Current Liabilities are $407.7 million (Q3 2025), $428.9 million (Q1 2025), and $438.0 million (Q4 2024).